Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Epithelial ovarian cancer is mostly diagnosed at late stage (III/IV), and the standard treatment for ovarian cancer includes primary debulking surgery and platinum-based adjuvant chemotherapy. However, scholars suggest that neoadjuvant chemotherapy can be used to reduce the tumor load and control the patient's condition. The aim of this study is to verify the efficacy of primary debulking surgery versus neoadjuvant chemotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Female patients over 18 years of age.

• ECOG 0-2

• Clinically confirmed epithelial ovarian or fallopian-tube cancer or primary peritoneal cancer

• FIGO2014 stage III/IV

• Sign the informed consent form

• Good compliance and agree to cooperate with survival follow-up

Exclusion Criteria:

• Patients with large abdominal masses or other reasons for not being able to tolerate surgical treatment

• Patients with severe medical comorbidities that cannot be corrected in the short term and are not suitable for tumor cytoreductive surgery

• Patients with contraindications to chemotherapy

• Patients with a history of psychotropic substance abuse and unable to quit or patients with mental disorders

• Patients with serious safety hazards or concomitant diseases that, in the judgment of the institution, would affect the patient's ability to complete the study